MJNA-LOGOMedical Marijuana, Inc. is the first publicly held company vested in the industrial hemp and legal cannabis industries. It is a company made up of a diversified portfolio of products, services, business, and technology focused completely on the production of high concentrate hemp oil products that are rich in cannabinoid. Medical Marijuana, Inc. trades in the OTC market under the symbol MJNA.

Medical Marijuana, Inc. aims to be the premier innovator in the hemp and cannabis industry, leveraging its team of professionals into sourcing, evaluating, and purchasing value-added products and companies. It strives to do so while simultaneously allowing them to keep their entrepreneurial spirit and integrity. The company also commits to create awareness within the industry, and develop environmentally friendly and economically stable businesses while increasing the value of their shareholders.

Medical Marijuana, Inc.’s range of products stem anywhere from proprietary and patented cannabinoid-based products to seed and stalk or unique high value extracts that are purposely formulated and manufactured for the cosmetics, nutraceutical, pharmaceutical, and food industries.

The company offers a varied and extensive selection of services, such as medical clinic management, development of existing industry business and product leaders, development of medical grade compounds, and development of cannabinoid-based health and wellness products. At present, Medical Marijuana, Inc. provides more than 80 proprietary and patent pending cannabinoid delivery methods, which are deemed more medically and socially acceptable compared to the usual industry methods.

Other services offered by Medical Marijuana, Inc. include licensing of its proprietary testing, labeling, genetics, packaging, production, tracking, and standardization of methods for the medicinal herb industry.

Medical Marijuana, Inc.’s portfolio companies include Canipa Holdings, Red Dice Holdings, Wellness Managed Services, HempMeds PX, KannaLife Sciences, Phytosphere, and CanChew Gum. Whether wholly owned or partially owned, all these businesses are integral part of Medical Marijuana, Inc. Featured products of these companies are Cibdex, Cibaderm, Dixie Botanicals, and Real Scientific Hemp Oil.


Yahoo! Finance: MJNA News

Latest Financial News for MJNA

Medical Marijuana, Inc. Subsidiary HempMeds® Welcomes X Games World Record-Holding Skateboarder Italo Penarrubia as Newest Brand Ambassador

MJNA Medical Marijuana, Inc. Subsidiary HempMeds® Welcomes X Games World Record-Holding Skateboarder Italo Penarrubia as Brand Ambassador SAN DIEGO, March 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® is proud to welcome X Games world record-holding skateboarder Italo Penarrubia as its newest brand ambassador. "We are excited to bring Penarrubia on as a part of our team and it is heart-warming to know how much our products have helped him over the years. We believe his support and recognition will help us further educate athletes and the general public on the health and wellness benefits of hemp-based cannabidiol (CBD) products," said HempMeds® CEO Raul Elizalde. Penarrubia is a renowned skateboarder and has performed in several X Games competitions, including his most recent appearance in X Games Minneapolis in 2019. At the 2017 X Games in Minneapolis, he earned a world record for the highest SKB Big Air height ever recorded at the X Games. After spending several years training in the U.S., Penarrubia recently relocated back to Brazil to continue his career and raise his family. “I have been using HempMeds’ CBD products for years to aid in recovery after long days of training,” said Penarrubia. “My goal is to help bridge the knowledge gap for athletes around the world that could benefit from using CBD but are afraid or unsure of how to use the products.” To learn more about HempMeds®, please visit the Company online at www.hempmedspx.com. About HempMeds® Founded in 2012, HempMeds® was the first company to bring hemp-based cannabidiol (CBD) oil products to market in the U.S. As a subsidiary of Medical Marijuana, Inc., HempMeds is the exclusive distributor for premium brands including Real Scientific Hemp Oil™ and Dixie Botanicals®, and operates in all 50 states and 40 countries. HempMeds® is the only company to have its CBD products listed in the Prescribers’ Digital Reference (PDR), the only company invited to speak to the World Health Organization and FDA on the benefits of CBD, and one of the first to be certified by the U.S. Hemp Authority. To learn more, please visit www.hempmedspx.com. About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company's flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.com Investor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.com Attachment MJNA

Medical Marijuana, Inc. Subsidiary Kannaway® Announces Positive Preliminary Results of Validcare Clinical Study on CBD Liver Toxicity

SAN DIEGO, CA, March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, reports today that its subsidiary Kannaway® participated in, and today announces the recent positive results, of the Validcare clinical study. The study used Kannaway®’s hemp-derived cannabidiol (CBD) products as a part of its efforts to meet the Food and Drug Administration (FDA)’s request for data on the use of botanical CBD with regard to potential liver toxicity issues, which seem to occur with the pharmaceutical version of CBD. According to Validcare’s team of principal investigators, the study showed no evidence of liver toxicity in the 839 trial participants who ingested oral forms of hemp-derived CBD for a minimum of 60 days. The investigators met with the Food and Drug Administration (FDA) Cannabis Product Council (formerly known as the Cannabis Work Group) on Monday, March 15, to share these findings and answer the organization’s March 5, 2020, request for science-based data to help determine the appropriate regulatory path for hemp-derived CBD products. Blood markers for ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase), ALP (Alkaline Phosphatase), and Bilirubin levels were examined during the study. “These study results help support the work that we’ve been doing in Mexico and Brazil to study CBD’s safety and efficacy,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We hope to continue to participate in similar future studies so that the world can continue to have expanded access to high-quality botanical products. I am glad to see participating stakeholders with longer-term visions banding together to make industry-wide progress that ultimately will benefit end consumers. Our company is involved with similar research in Europe in conjunction with the European Industrial Hemp Association (EIHA).” Brands that participated in this study provided funding, product, certificates of authenticity, and assisted with the recruitment of adult US-based consumers. The use of Validcare’s decentralized clinical research platform and partnership with national laboratories enabled participants and principal investigators to successfully complete this first cohort, despite the pandemic, and compile and deliver results to brands and the FDA within six weeks. “As the creators of some of the first testing measures for the entire CBD industry, many that are still used by other companies today, we are proud to be a part of this study and continue to be leaders in CBD safety testing,” said Kannaway® CEO Blake Schroeder. “Providing the highest-quality, safest products on the market is something we are proud of.” About Kannaway® Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products. About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.com Investor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.com

Medical Marijuana, Inc. Subsidiary HempMeds® Applauds Mexico’s Chamber of Deputies for Approving Federal Marijuana Legalization

SAN DIEGO, CA, March 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® applauds Mexico’s Chamber of Deputies for approving a bill to federally legalize marijuana. “At HempMeds Mexico, we have watched both regulations and public sentiment shift in favor of cannabis legalization over the years and see this recent legislation as one step closer to federal cannabis legalization in Mexico,” said HempMeds® CEO Raúl Elizalde. “With that said, we hope that legislators will analyze the over-regulation of hemp products in the next stages of the legislative process and focus on non-psychoactive cannabis derivatives without recreational or medical purposes, like cosmetics, food, and others.” Elizalde is a well-known medical cannabis advocate in Mexico and helped legalize medical cannabis in the country. His advocacy began several years ago with his fight to gain access to CBD hemp oil for his daughter Grace. Recently, Elizalde has been featured in multiple top-tier media outlets such as NBC News, Yahoo, Border Report, Univision and MSN, regarding his thoughts on legalization. As a cannabis industry veteran of over a decade, Medical Marijuana, Inc. CEO Dr. Stuart Titus is a well-known thought leader in global cannabis advocacy. He has worked to legalize CBD in several Latin American countries and helped the Company receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay. In a March 8, 2021, Reuters article about Mexico’s recent progress toward legalization, Dr. Titus commented: “Much of Mexico’s cannabis has been black market and the resulting war on drugs has proven to be a huge failure. The right solution: legalize, tax and regulate this market.” Several additional top-tier media outlets shared Dr. Titus’ commentary, including U.S. News & World Report, The Globe and Mail, NASDAQ, National Post, and more. To learn more about HempMeds®, please visit the Company online at www.hempmedspx.com. About HempMeds® Founded in 2012, HempMeds® was the first company to bring hemp-based cannabidiol (CBD) oil products to market in the U.S. As a subsidiary of Medical Marijuana, Inc., HempMeds is the exclusive distributor for premium brands including Real Scientific Hemp Oil™ and Dixie Botanicals®, and operates in all 50 states and 40 countries. HempMeds® is the only company to have its CBD products listed in the Prescribers’ Digital Reference (PDR), the only company invited to speak to the World Health Organization and FDA on the benefits of CBD, and one of the first to be certified by the U.S. Hemp Authority. To learn more, please visit www.hempmedspx.com. About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.com Investor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.com

Medical Marijuana, Inc. Subsidiary Kannaway® Announces February 2021 as the Best Month in Company History for Japan Division

SAN DIEGO, CA, March 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Japanese division of its subsidiary Kannaway® had its best sales month ever in Company history in February 2021. “When we first entered the Japanese market in late 2019, we were one of the first companies offering cannabidiol (CBD) products in the country and saw a great opportunity to give consumers the high-quality products they had been asking for,” said Kannaway® CEO Blake Schroeder. “Since then, our team has done tremendous work expanding our reach and footprint in Japan.” The Japanese CBD market looks to continue rapidly expanding in the coming years. According to Research and Markets, the global CBD oil market is expected to reach $5.3 billion by 2025 with Asia-Pacific as one of the fastest-growing regions. “While leading our team in Japan, I have seen the positive response to our offerings in the country first-hand. Our team has shown what can be done with hard work and a distinguishing product offering and I look forward to our further growth,” said Kannaway® Japan Division General Manager Peter Dale. To learn more about Kannaway®, please visit the Company online at https://www.kannaway.com/. About Kannaway® Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products. About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.com Investor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.com

Medical Marijuana, Inc. Subsidiary Kannaway® Receives BSCG Certified Drug-Free Approval for Its Pure Gold CBD

Pure Gold Recognized as Free of Substances Banned by US Anti-Doping Agency (USADA) and Professional Sports Leagues SAN DIEGO, CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has received Certified Drug Free approval from the Banned Substances Control Group (BSCG), a leading third-party certification and testing provider of dietary supplements and natural products, for its broad-spectrum cannabidiol (CBD) product Pure Gold. “As pioneers in the CBD industry, we were one of the first companies to conduct third-party testing on all of our products and provide those results to our customers,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “This certification furthers our dedication to providing athletes and general consumers alike the confidence to enjoy Pure Gold CBD without the fear of drug testing.” BSCG is the standard in testing for third-party certification that ensures products meet quality specifications and are not contaminated with drugs or agents that can lead to health concerns or positive drug tests. The BSCG Certified Drug Free program requires companies to submit their products through a thorough toxicology review, ingredient evaluation, Good Manufacturing Practices (GMP) quality control process review, and continual random product testing. It provides protection against drugs on the World Anti-Doping Agency (WADA) Prohibited List as well as prescription over-the-counter (OTC) and illicit drugs not banned in sports. “The greatest value that we can provide our customers with is trust and we aim to offer this time and time again by guaranteeing that our products are of the highest quality, safe, consistent, and accurately labeled,” said Kannaway® CEO Blake Schroeder. “We take every opportunity we are given to test and certify our products and hope that consumers see that as our commitment to them." To learn more about BSCG or view Kannaway’s certification, please visit https://kannaway.com/news/content/pure-gold-1500-mg-receives-certified-cbd-seal-by-bscg,4,822.html. About Kannaway® Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products. About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.com Investor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.com